About

Introducing ReciBioPharm, Recipharm's biologics business combining the capabilities of recently acquired CDMOs Arranta Bio, GenIbet and Vibalogics. Our expanded biologics drug development and manufacturing services encompass technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, recombinant proteins, nucleic acid-based mRNA and plasmid DNA production. Established in 1995, Recipharm’s manufacturing, fill-finish, and delivery-device services canvass a wide variety of drug dosage forms and modalities. Recipharm is an industry leading CDMO with over 30 facilities and 9,000 employees globally – servicing companies that are developing small-molecules, biologics, and drug-device combinations. About Recipharm Introducing ReciBioPharm, Recipharm's biologics business combining the capabilities of acquired CDMOs Arranta Bio, GenIbet and Vibalogics. Our expanded biologics drug development and manufacturing services encompass technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, recombinant proteins, nucleic acid-based mRNA and plasmid DNA production. Established in 1995, Recipharm’s manufacturing, fill & finish, and delivery services encompass a wide variety of drug dosage forms and modalities. Recipharm is an industry leading CDMO with over 30 facilities and 7,400 employees globally – supporting companies that are developing small molecules and biologics. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US. About Recipharm Introducing ReciBioPharm, Recipharm's biologics business combining the capabilities of acquired CDMOs Arranta Bio, GenIbet and Vibalogics. Our expanded biologics drug development and manufacturing services encompass technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, recombinant proteins, nucleic acid-based mRNA and plasmid DNA production. Established in 1995, Recipharm’s manufacturing, fill & finish, and delivery services encompass a wide variety of drug dosage forms and modalities. Recipharm is an industry leading CDMO with over 30 facilities and 7,400 employees globally – supporting companies that are developing small molecules and biologics. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US. Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including, sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and, pharmaceutical product development. Its biologics segment, ReciBioPharm, works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical and commercial development and manufacture for new biological modalities. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US. Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including, sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and, pharmaceutical product development. Its Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical and commercial development and manufacture for new biological modalities. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US.